AGM/EGMApr 30, 2026, 04:42 PM
AGEN AGM: Equity Plan Increase, Option Exchange, Zydus Deal
AI Summary
Agenus Inc. announced its Annual Meeting of Stockholders for June 16, 2026, presenting proposals including the election of directors, an increase of 5,000,000 shares for its 2019 Equity Incentive Plan, and a one-time stock option exchange program. The company highlighted significant progress in 2025 and early 2026, including durable clinical data for BOT+BAL, first revenues from early access programs in France, and the initiation of the Phase 3 BATTMAN trial. Agenus also strengthened its balance sheet through a $91.0 million strategic collaboration with Zydus Lifesciences and reduced its annualized operating burn to approximately $50 million.
Key Highlights
- Zydus Lifesciences strategic collaboration closed for $91.0 million.
- Annualized operating burn reduced from over $200 million to approximately $50 million.
- BOT+BAL demonstrated 39% two-year overall survival across more than nine tumor types.
- 42% of MSS mCRC patients (n=123) treated with BOT+BAL were alive at two years.
- Registrational Phase 3 BATTMAN trial initiated with first patient enrolled in March 2026.
- France authorized reimbursed compassionate access for BOT+BAL in September 2025.
- Proposed increase of 5,000,000 shares for the 2019 Equity Incentive Plan.
- Proposed one-time stock option exchange program with premium strike for executives/directors.